The Chemistry Speaker Series Committee are excited to announce the second talk for Spring 2022:
High Throughput Mass Spectrometry in Early Drug Discovery
- Speaker: Mr. Stefan Thibodeaux at Novartis
- Mr. Stefan Thibodeaux has been working in the pharmaceutical industry for over 20 years. During his time at Eli Lilly, he co-developed Eli Lilly’s high throughput mass spectrometry capabilities before moving on to Novartis where he has led a team focused on developing novel assay for drug discovery project.
- March 15th 2:00 – 3:00 PM (virtual – Microsoft TEAMS)
- Abstract: High-throughput mass spectrometry (HTMS), once a niche technique, is now embedded in all aspects of early drug discovery. The major diving force for this expansion is the continual drive for a reduction in the design, make, test cycle (DMT) in early drug discovery. Typically, HTMS is thought of as the ability to analyze six samples or more per minute, and it is commonly used to provide data on metabolic stability, CYP inhibition, permeability, solubility, biochemical screening, bio-catalysis screening, and reaction monitoring. Yet, as early drug discovery chemistry adopts more parallel and plate-based synthetic chemistry strategies, a corresponding decrease in sample analysis time is needed to avoid an increase in DMT cycle times. This talk will focus on the historical development of HTMS instrumentation and the current push into higher throughput techniques that can analyze a 384-well plate in 10 minutes instead of 60-90 minutes and how the increase in the sensitivities of mass spectrometers has made this evolution possible and how this increase in throughput is enabling new ways of thinking about problems in early drug discovery.